Free tool
FAERS Monitor: Ozempic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213051 or its brand name (Ozempic, Semaglutide). Reports on generic versions are filed under their own applications.
Reports
78,023
Serious
39,105
50% of reports
Hospitalization
15,565
Death reported
1,364
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea11,150
- off label use7,890
- vomiting7,332
- diarrhoea6,833
- decreased appetite5,107
- constipation4,976
- weight decreased4,777
- impaired gastric emptying4,175
- product use in unapproved indication3,761
- blood glucose increased3,460
- fatigue3,252
- headache3,240
- abdominal pain upper3,197
- wrong technique in product usage process3,100
- weight increased2,869
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 14 |
| 2017 | 14 |
| 2018 | 1,142 |
| 2019 | 1,596 |
| 2020 | 3,514 |
| 2021 | 4,563 |
| 2022 | 6,320 |
| 2023 | 9,506 |
| 2024 | 14,313 |
| 2025 | 20,019 |
| 2026 | 17,010 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,976,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| impaired gastric emptyingSignal | 4,175 | 118.5 | 114.4 | 337,774 |
| constipationSignal | 4,976 | 6.3 | 6.1 | 21,763 |
| decreased appetiteSignal | 5,107 | 6.0 | 5.9 | 21,226 |
| blood glucose increasedSignal | 3,460 | 5.0 | 4.9 | 11,043 |
| weight decreasedSignal | 4,777 | 4.7 | 4.5 | 13,746 |
| vomitingSignal | 7,332 | 4.3 | 4.2 | 18,377 |
| abdominal pain upperSignal | 3,197 | 4.2 | 4.1 | 7,854 |
| wrong technique in product usage processSignal | 3,100 | 4.2 | 4.0 | 7,432 |
| product use in unapproved indicationSignal | 3,761 | 4.1 | 4.0 | 8,918 |
| nauseaSignal | 11,150 | 3.8 | 3.8 | 23,965 |
| weight increasedSignal | 2,869 | 3.5 | 3.4 | 5,071 |
| diarrhoeaSignal | 6,833 | 2.9 | 2.8 | 8,517 |
| off label useSignal | 7,890 | 2.4 | 2.4 | 6,946 |
| headache | 3,240 | 1.4 | 1.3 | 371 |
| fatigue | 3,252 | 1.1 | 1.1 | 48 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.